This white paper explores how IRBM uses digital pathology and multiplex imaging to characterize cellular ecosystems and tissue architecture, while considering the potential of emerging spatial multi-omics approaches. Drawing on examples from oncology and neurodegeneration, it highlights the value of preserving spatial context for target and biomarker assessment and discusses how computational image analysis can help extract biologically meaningful insights in drug discovery.
Sponsored by
IRBM
IRBM is a leading drug discovery organization with a proven track record of bringing three therapeutics to market across oncology, neurology, infectious, and rare diseases. Independent since 2010, the company partners with global biotech, pharma, and research institutions to deliver both standalone specialized services and fully integrated, efficient drug discovery programs.